Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
Study indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complications retrieved 22 July 2024 from https://medicalxpress.com/news/2024-07-surge-glp-1ra-prescriptions-obesity.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study reveals exercise and GLP-1 RA combination preserves bone health during weight lossCombining exercise with GLP-1 RA liraglutide results in significant weight loss while preserving bone health in adults with obesity.
Weiterlesen »
New study reveals how GLP-1 receptor agonists enhance preingestive fullnessGLP-1 receptor agonists promote the feeling of fullness before eating via neurons in the dorsomedial hypothalamus, according to a new study. The findings offer new insights into the neural pathways by which GLP-1 receptor agonists increase the feeling of fullness to prevent overconsumption of food, which is key in mitigating obesity.
Weiterlesen »
Exercise and GLP-1 RA appears effective for weight loss while preserving bone mineral densityFor adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective for weight loss, while preserving bone health, according to a study published online June 25 in JAMA Network Open.
Weiterlesen »
GLP-1 drugs found to lower cancer risk in diabetes patientsResearch finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.
Weiterlesen »
Sister hormone of GLP-1 could lead to better weight-loss drugsMuch like the Cold War space race, the world's pharmaceutical giants are currently scrambling to produce the best weight-loss drug. They all want to be the first to explore the nooks and crannies of the body in order to be able to design the optimal drug. However, several pharmaceutical giants disagree on what the next step should be.
Weiterlesen »
Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesityIn a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.
Weiterlesen »